A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

NCT06362044 · clinicaltrials.gov ↗
COMPLETED
Status
89
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie